Zenas BioPharma Files 8-K for Bylaws and Financials
Ticker: ZBIO · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1953926
Sentiment: neutral
Topics: corporate-governance, financial-reporting
TL;DR
Zenas BioPharma filed an 8-K for corporate updates and financials. Nothing major.
AI Summary
Zenas BioPharma, Inc. filed an 8-K on September 16, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorporated in Delaware, is based in Waltham, MA, and operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates routine corporate actions and financial reporting, providing transparency to investors about the company's operational and legal status.
Risk Assessment
Risk Level: low — The filing pertains to standard corporate reporting and does not indicate any significant new risks or material events.
Key Players & Entities
- Zenas BioPharma, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Principal executive offices
- September 16, 2024 (date) — Date of earliest event reported
FAQ
What specific amendments were made to Zenas BioPharma's articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information.
What is the primary business of Zenas BioPharma, Inc.?
Zenas BioPharma, Inc. operates in the Pharmaceutical Preparations industry, with SIC code 2834.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on September 16, 2024.
Where are Zenas BioPharma's principal executive offices located?
The principal executive offices of Zenas BioPharma are located at 1000 Winter Street, Suite 1200, Waltham, MA 02451.
What is the SEC file number for Zenas BioPharma, Inc.?
The SEC file number for Zenas BioPharma, Inc. is 001-42270.
Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 13.2 · Accepted 2024-09-16 16:04:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ZBIO The Nasdaq Global Se
Filing Documents
- tm2332800d24_8k.htm (8-K) — 32KB
- tm2332800d24_ex3-1.htm (EX-3.1) — 41KB
- tm2332800d24_ex3-2.htm (EX-3.2) — 75KB
- 0001104659-24-100177.txt ( ) — 355KB
- zbio-20240916.xsd (EX-101.SCH) — 3KB
- zbio-20240916_lab.xml (EX-101.LAB) — 33KB
- zbio-20240916_pre.xml (EX-101.PRE) — 22KB
- tm2332800d24_8k_htm.xml (XML) — 4KB
03
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 16, 2024, in connection with the consummation of the initial public offering (the "IPO") of shares of common stock, par value $0.0001 per share, of the Company ("Common Stock"), the Company filed a second restated certificate of incorporation (the "Restated Certificate") with the Secretary of State of the State of Delaware, which became effective upon filing. The Company's board of directors and stockholders previously approved the Restated Certificate to be filed in connection with, and to be effective upon, the consummation of the IPO. The Restated Certificate amends and restates the Company's certificate of incorporation in its entirety to, among other things, (i) authorize 175 million shares of Common Stock, (ii) eliminate all references to previously existing series of preferred stock, (iii) authorize 25 million shares of undesignated preferred stock, par value $0.0001 per share, that may be issued from time to time, in one or more series, with the approval of the Company's board of directors and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting. The foregoing description of the Restated Certificate is qualified by reference to the Restated Certificate, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference. On September 16, 2024, in connection with the consummation of the IPO, the amended and restated bylaws of the Company (the "Amended and Restated Bylaws"), previously approved by the Company's board of directors and stockholders, became effective. The Amended and Restated Bylaws amend and restate the Company's bylaws in their entirety to, among other things, (i) establish procedures relating to the presentation of stockholder proposals at stockholder meetings, (ii) establish procedures relating to the nomination of directors, (iii) modify the indemnification prov
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Second Restated Certificate of Incorporation of Zenas BioPharma, Inc. 3.2 Amended and Restated Bylaws of Zenas BioPharma, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENAS BIOPHARMA, INC. By: /s/ Jennifer Fox Name: Jennifer Fox Title: Chief Business Officer and Chief Financial Officer Date: September 16, 2024